Navigation Links
Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries
Date:2/11/2008

SOUTH SAN FRANCISCO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) and Sigma-Tau SpA have announced an agreement granting an exclusive license to Sigma-Tau for the marketing and distribution of Anesiva's Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system in six European countries: Italy, France, Germany, Netherlands, Belgium and Luxembourg. Under the terms of the agreement, Sigma-Tau will oversee all necessary regulatory filings, and will be responsible for all marketing and sales of Zingo in their territory.

"In Sigma-Tau, we have selected an experienced partner that can quickly and effectively maximize the Zingo opportunity in Europe and we look forward to an excellent collaborative relationship. Sigma-Tau has a proven commercial infrastructure, including a hospital sales force, and a strong network in Europe," said John P. McLaughlin, chief executive officer of Anesiva. "This licensing agreement covers the majority of Europe and we are currently in advanced discussions with other potential partners for certain additional countries."

"Sigma-Tau seeks to help improve health and quality of life for all. Our agreement to bring Zingo to European markets fits perfectly with this aim, and we are eager to make this FDA-approved product available to patients who otherwise might not have access to it for the reduction of pain associated with peripheral venous access procedures," said Ugo Di Francesco, Executive Vice President and Chief Executive Officer at Sigma-Tau.

The agreement between Anesiva and Sigma-Tau includes an upfront payment to Anesiva and transfer price, as well as milestone payments; additional terms were not disclosed.

About Zingo(TM)

Zingo(TM) is an easy-to-administer, single-use, needle-free system that delivers sterile lidocaine powder to provide topical, local analgesia to reduce the pain associated with peripheral I.V. insertions or blood draws. Zingo's rapid onset of action allows intravenous line placement or venipuncture to begin one to three minutes after administration. Zingo was approved by the U.S. Food and Drug Administration (FDA) in August 2007 to reduce the pain associated with peripheral I.V. insertions or blood draws in children three to 18 years of age. In clinical trials, the most common adverse events with Zingo were redness (erythema), red dots (petechiae) and swelling (edema).

About Sigma-Tau Group

Sigma-Tau is a leading research-based Italian pharmaceutical company with a 2007 consolidated turnover equal to approximately US$980 million, and over 2,500 employees worldwide. Therapeutic areas in which the company's research and development are focused include cardiovascular disease, metabolism, oncology, immunology, and central and nervous system disorders, with 47 projects, 30 clinical indications studied with 17 proprietary molecules, most of which are new and original. Sigma-Tau has operating subsidiaries throughout Europe and the United States and maintains a presence in all of the world's major pharmaceutical markets. For additional information about Sigma-Tau, please visit http://www.sigma-tau.it.

About Anesiva and its Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA, USA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anesiva Announces Hiring of Sales Force for FDA-Approved Product Zingo(TM)
2. Anesiva Announces Upcoming Webcasts and Conference Participation
3. Anesiva to Announce Third Quarter 2007 Financial Results and Host Webcast Conference Call on November 1, 2007
4. Anesiva to Present at BIO InvestorForum on October 11, 2007
5. Anesiva to Unveil Zingo(TM) Commercialization Plans
6. URAC Announces Four More Companies in Process to Earn New Pharmacy Quality Management Accreditations
7. MGT Capital Investments, Inc. Announces Subsidiarys Preliminary Agreement to Acquire Maydeal.com
8. Dialysis Corporation of America Announces Opening of New Dialysis Center in Ohio
9. Rural/Metro Announces Results for Fiscal 2008 Second Quarter
10. Brookdale Senior Living Announces Changes in Senior Management and Board of Directors
11. Tubbs Jones Announces Over $36 Million in Construction Projects for Cleveland VA Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... Talent Management Solutions as part of their continued efforts to provide innovative offerings ... develop the best IT resources and build dynamic, high-performing teams to address healthcare ...
(Date:7/26/2017)... Bethesda, Maryland (PRWEB) , ... ... ... International Society for Pharmaceutical Engineering (ISPE) will host its 2017 Process ... September. These concurrent events offer comprehensive solutions to process validation lifecycle challenges ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... “We are ... offer the ability for patients to schedule an appointment online in real time,” said ... the Six Month Smiles provider directory will bring more Six Month Smiles patients to ...
(Date:7/26/2017)... ... July 26, 2017 , ... The Amnesty Rally 2017 will be ... Park at 3313 Bernstein Park Drive in Monroe (adjacent to the Louisiana Purchase Gardens ... help reduce gun violence throughout Monroe. Citizens can turn in unregistered, illegally-held and imitation ...
(Date:7/25/2017)... , ... July 25, 2017 , ... “Now Hiring!” is ... Louis, Missouri. The company has achieved record-breaking sales for over 30 consecutive years ... next 12 months. , The upcoming year offers excitement and growth at HDIS, following ...
Breaking Medicine News(10 mins):
(Date:7/19/2017)... 2017  Mako Medical Laboratories partnered with Secretary Strickland, ... Assistance Fund (MFA) to bring 140 soldiers back home ... their families one last time before being deployed. Mako ... and logistics needed for these soldiers. "Mako Medical Laboratories ... families. We just wish we could bring them all ...
(Date:7/13/2017)... 13, 2017  Centurion Medical Products, a leader in medical product ... fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part ... alleviate patient pain while preventing unneeded emergency department admission due to ...
(Date:7/11/2017)... Zymo Research Corp., also known as ,The Epigenetics Company, announced today the ... precise manner using the myDNAge ™ test. Based on Horvath,s Clock, ... genetics and biostatistics at the David Geffen School of Medicine at ... proprietary DNAge ™ technology is used to analyze DNA methylation patterns ... ...
Breaking Medicine Technology: